$1.88
+0.05 (+2.73%)
Open$1.83
Previous Close$1.83
Day High$1.92
Day Low$1.79
52W High$7.80
52W Low$1.01
Volume—
Avg Volume704.1K
Market Cap123.81M
P/E Ratio—
EPS$-1.75
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,972.9% upside
Current
$1.88
$1.88
Target
$38.97
$38.97
$29.17
$38.97 avg
$44.78
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.00M | 76.19M | 65.35M |
| Net Income | -1,399,615 | -1,371,226 | -1,459,846 |
| Profit Margin | -1.8% | -1.8% | -2.2% |
| EBITDA | -1,495,155 | -1,465,448 | -1,363,438 |
| Free Cash Flow | -1,111,108 | -1,336,142 | -1,081,347 |
| Rev Growth | +16.0% | +7.1% | -1.4% |
| Debt/Equity | 0.13 | 0.12 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |